X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare GSK Pharma with Divis Laboratories - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GSK PHARMA vs DIVIS LABORATORIES - Comparison Results

GSK PHARMA    Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

DIVIS LABORATORIES 
   Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GSK PHARMA DIVIS LABORATORIES GSK PHARMA/
DIVIS LABORATORIES
 
P/E (TTM) x 65.0 31.3 207.3% View Chart
P/BV x 10.4 5.4 192.2% View Chart
Dividend Yield % 1.2 0.9 132.9%  

Financials

 GSK PHARMA   DIVIS LABORATORIES
EQUITY SHARE DATA
    GSK PHARMA
Mar-17
DIVIS LABORATORIES
Mar-17
GSK PHARMA/
DIVIS LABORATORIES
5-Yr Chart
Click to enlarge
High Rs3,8381,222 314.1%   
Low Rs2,637784 336.4%   
Sales per share (Unadj.) Rs354.2153.1 231.3%  
Earnings per share (Unadj.) Rs39.839.9 99.5%  
Cash flow per share (Unadj.) Rs42.944.6 96.1%  
Dividends per share (Unadj.) Rs30.0010.00 300.0%  
Dividend yield (eoy) %0.91.0 92.9%  
Book value per share (Unadj.) Rs236.9201.8 117.4%  
Shares outstanding (eoy) m84.70265.47 31.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x9.16.6 139.5%   
Avg P/E ratio x81.425.1 324.3%  
P/CF ratio (eoy) x75.522.5 335.7%  
Price / Book Value ratio x13.75.0 274.9%  
Dividend payout %75.425.0 301.4%   
Avg Mkt Cap Rs m274,216266,266 103.0%   
No. of employees `0004.79.7 48.2%   
Total wages/salary Rs m4,8304,687 103.0%   
Avg. sales/employee Rs Th6,387.04,175.0 153.0%   
Avg. wages/employee Rs Th1,028.3481.5 213.6%   
Avg. net profit/employee Rs Th717.11,089.3 65.8%   
INCOME DATA
Net Sales Rs m30,00040,643 73.8%  
Other income Rs m728749 97.2%   
Total revenues Rs m30,72841,392 74.2%   
Gross profit Rs m4,19014,460 29.0%  
Depreciation Rs m2631,233 21.3%   
Interest Rs m023 0.0%   
Profit before tax Rs m4,65513,953 33.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m4570-   
Tax Rs m1,7443,349 52.1%   
Profit after tax Rs m3,36810,604 31.8%  
Gross profit margin %14.035.6 39.3%  
Effective tax rate %37.524.0 156.1%   
Net profit margin %11.226.1 43.0%  
BALANCE SHEET DATA
Current assets Rs m16,74240,105 41.7%   
Current liabilities Rs m7,2026,595 109.2%   
Net working cap to sales %31.882.5 38.6%  
Current ratio x2.36.1 38.2%  
Inventory Days Days52119 43.7%  
Debtors Days Days2181 25.8%  
Net fixed assets Rs m8,63519,995 43.2%   
Share capital Rs m847531 159.5%   
"Free" reserves Rs m19,22253,043 36.2%   
Net worth Rs m20,06953,574 37.5%   
Long term debt Rs m100-   
Total assets Rs m30,03861,585 48.8%  
Interest coverage xNM618.4-  
Debt to equity ratio x00-  
Sales to assets ratio x1.00.7 151.3%   
Return on assets %11.217.3 65.0%  
Return on equity %16.819.8 84.8%  
Return on capital %25.526.1 97.6%  
Exports to sales %00-   
Imports to sales %025.2 0.0%   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNA10,259 0.0%   
Fx inflow Rs m52835,384 1.5%   
Fx outflow Rs m7,19310,399 69.2%   
Net fx Rs m-6,66524,985 -26.7%   
CASH FLOW
From Operations Rs m2,36011,493 20.5%  
From Investments Rs m3,008-11,372 -26.5%  
From Financial Activity Rs m-5,108-93 5,486.1%  
Net Cashflow Rs m26028 916.5%  

Share Holding

Indian Promoters % 0.0 52.0 -  
Foreign collaborators % 50.7 0.0 -  
Indian inst/Mut Fund % 10.2 11.8 86.4%  
FIIs % 23.8 19.0 125.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 15.4 17.2 89.5%  
Shareholders   102,036 31,796 320.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GSK PHARMA With:   MERCK LTD  STERLING BIOTECH  JUBILANT LIFE SCIENCES  AUROBINDO PHARMA  IPCA LABS  

Compare GSK PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Of Global Markets Hitting Record Highs and Top Stocks in Action During the Week(RoundUp)

Global stock markets ended the week on a positive note. Benchmark indices in US grew by 1% during the week. The Down Jones Industrial Average topped the 26,000.

Related Views on News

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

Resolutions for 2018 - by others(The Honest Truth)

Jan 8, 2018

Ten quirky new year resolutions. Guess by whom?

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GSK PHARMA SHARE PRICE


Jan 19, 2018 (Close)

TRACK GSK PHARMA

  • Track your investment in GSK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

GSK PHARMA - ALEMBIC LTD COMPARISON

COMPARE GSK PHARMA WITH

MARKET STATS